(Reuters) - The U.S. Food and Drug Administration said on Friday it approved Ariad Pharmaceuticals Inc's drug to treat two rare types of blood cancer, three months ahead of the review date. Iclusig was approved to treat chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. The drug, generically known as ponatinib, is being granted an orphan product status, intended for drugs that aim to treat rare diseases. ... via Health News Headlines - Yahoo! News Read More Here..
No comments:
Post a Comment